Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Symphony Technology Group in connection with the public offer for IBS
Mandate

Vinge advises Symphony Technology Group in connection with the public offer for IBS

May 18, 2011

Vinge advises Symphony Technology Group in connection with the public offer for IBS AB, listed on NASDAQ OMX First North. Symphony Technology Group offers SEK 1.75 in cash per share in IBS, regardless of share class, and the board of directors of IBS has unanimously recommended the shareholders to accept the offer. Shareholders representing approximately 75.5 percent of the shares and 81.4 percent of the votes have irrevocably undertaken to accept the offer.

Vinge’s team consists of partner in charge Pontus Enquist as well as Emil Hedberg. In addition, Fabian Ekeblad has advised on banking and finance issues, and Johan Mattsson, Maria Eierborg, Moa Bergsten, Mikael Satama Granberg, Per Westman and Anders Frick, among other, have participated in the due diligence carried out on IBS.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

 Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026